NUS signed a Memorandum of Understanding with Agilent Technologies Singapore Pte. Ltd. This MoU with Dr. Chester Drum, of the Department of Medicine, NUS Yong Loo Lin School of Medicine, the Cardiovascular Research Institute (CVRI) and National University Heart Centre Singapore (NUHCS) allows access to the latest suite of bioanalytical equipment at the Agilent’s Proof of Concept Lab (situated on the NUS campus).
The analytical equipment at Agilent’s lab includes 6550 Q-TOF LC/MS that enables complex qualitative and quantitative detection of products from drug metabolism and pharmacokinetics and Capillary Electrophoresis System model 7100 which can detect small amounts of charged substances like biomolecules.
Drum’s lab works on creating real-time readouts on the risk-benefit of commonly prescribed medications in order to provide safer and more efficient use of these drugs by the patients. This collaboration could also provide insight into patient-specific metabolomics which could eventually lead to the development of novel analytics for personalized cardiovascular-care paradigm.
Source: Agilent’s press release can be found here.